Cigarette smoking and the onset and persistence of major depressive disorder among adults in the United States: 1994–2005

2015 ◽  
Vol 146 ◽  
pp. e33
Author(s):  
Michael Zvolensky ◽  
Jafar Bakhshaie ◽  
Renee Goodwin
2012 ◽  
Vol 26 (4) ◽  
pp. 235-241
Author(s):  
David A. Sclar ◽  
Linda M. Robison ◽  
Lawrence J. Cohen ◽  
Kimberly K. Laubmeier ◽  
Iftekhar D. Kalsekar ◽  
...  

2010 ◽  
Vol 13 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Qiuhua Shen ◽  
Sandra Bergquist-Beringer ◽  
Valmi D. Sousa

Objective: The association between depression and insulin resistance has been evaluated in previous studies with conflicting results. This study aimed to explore the relationship between major depressive disorder (MDD) and insulin resistance among nondiabetic young adult men and women in the United States. Method: Analyses of cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 1999—2002, were conducted. The nationally representative sample consisted of 279 men and 358 women aged 20—39 years. MDD was determined by the WHO Composite International Diagnostic Interview (CIDI). Insulin resistance was measured by the homeostasis model assessment for insulin resistance. Results: Of 637 subjects, 16 men and 18 women had MDD (weighted percentage = 6.6%, SE = 1.2). Using logistic regression, no significant association was found between MDD and insulin resistance among the nondiabetic young adults in bivariate analysis (β = -0.01, OR = 0.99, 95% CI = [0.38, 2.57], p = .98). A significant interaction effect between gender and MDD was observed. For men, MDD was negatively associated with insulin resistance after adjusting for age, race/ethnicity, waist circumference, smoking status, systolic blood pressure and triglyceride level (β = -2.12, OR = 0.12, 95% CI = [0.02, 0.62], p = .01). No significant association between MDD and insulin resistance among women was found (β = 0.61, OR = 1.84, 95% CI = [0.47, 7.14], p = .38). Conclusions: Overall findings suggest there is no significant association between MDD and insulin resistance among nondiabetic young adults aged 20—39 years. However, gender differences in this relationship were noted.


2014 ◽  
Vol 4 (1) ◽  
pp. 27-30
Author(s):  
Clint Ross

Levomilnacipran (Fetzima™) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication.


2012 ◽  
Vol 15 (4) ◽  
pp. A81
Author(s):  
H.C. Lin ◽  
R.P. Clodfelter ◽  
C.H. Lee ◽  
R. Balkrishnan ◽  
S.R. Feldman

2021 ◽  
pp. 326-332
Author(s):  
Ahmed T. Makhlouf

Anxiety disorders are the most common psychiatric syndromes in the United States. About 29% of adults will receive a diagnosis of an anxiety disorder during their lifetime, and almost one-fifth of adults have symptoms of anxiety in any given year. Globally, anxiety disorders are responsible for 10% of the disability-adjusted life years for all psychiatric and neurologic disorders, second only to major depressive disorder.


2021 ◽  
Vol 24 ◽  
pp. S129-S130
Author(s):  
M. Zhdanava ◽  
J. Voelker ◽  
D. Pilon ◽  
J.J. Sheehan ◽  
L. Morrison ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document